MB Lanktree, A Haghighi, I di Bari… - Clinical journal of the …, 2021 - journals.lww.com
Autosomal dominant polycystic kidney disease is the most common monogenic cause of ESKD. Genetic studies from patients and animal models have informed disease …
K Dong, C Zhang, X Tian, D Coman, F Hyder, M Ma… - Nature …, 2021 - nature.com
Initiation of cyst formation in autosomal dominant polycystic kidney disease (ADPKD) occurs when kidney tubule cells are rendered null for either PKD1 or PKD2 by somatic 'second …
JA Torres, SL Kruger, C Broderick, T Amarlkhagva… - Cell metabolism, 2019 - cell.com
Mild reduction in food intake was recently shown to slow polycystic kidney disease (PKD) progression in mouse models, but whether the effect was due to solely reduced calories or …
Autosomal dominant polycystic kidney disease (ADPKD) is generally a late-onset multisystem disorder characterized by bilateral kidney cysts, liver cysts, and an increased …
F Sasai, KL Rogers, DJ Orlicky… - American Journal …, 2022 - journals.physiology.org
Silica nanoparticles (SiNPs) released during the burning of sugarcane have been postulated to have a role in chronic kidney disease of unknown etiology. We tested the …
S Strubl, S Oehm, JA Torres, F Grundmann… - Clinical kidney …, 2022 - academic.oup.com
Background Our laboratory published the first evidence that nutritional ketosis, induced by a ketogenic diet (KD) or time-restricted diet (TRD), ameliorates disease progression in …
F Morioka, S Nakatani, H Uedono, A Tsuda… - Journal of Clinical …, 2023 - mdpi.com
Treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors may have pleiotropic and beneficial effects in terms of ameliorating of risk factors for the progression of autosomal …
A Dare, ML Channa, A Nadar - Biomedicine & Pharmacotherapy, 2021 - Elsevier
Abstract L-ergothioneine (L-egt) is a bioactive compound recently approved by the food and drug administration as a supplement. L-egt exerts potent cyto-protective, antioxidant and anti …